Business Description
Kangmei Pharmaceutical Co Ltd
NAICS : 325411
ISIN : CNE0000017M1
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.58 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.68 | |||||
Interest Coverage | 2.32 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.82 | |||||
Beneish M-Score | -2.07 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.6 | |||||
3-Year EPS without NRI Growth Rate | 79.1 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.04 | |||||
9-Day RSI | 58.15 | |||||
14-Day RSI | 58.54 | |||||
6-1 Month Momentum % | 6.49 | |||||
12-1 Month Momentum % | 2.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 0.84 | |||||
Cash Ratio | 0.16 | |||||
Days Inventory | 231.21 | |||||
Days Sales Outstanding | 146.24 | |||||
Days Payable | 196.83 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -40.7 | |||||
Shareholder Yield % | 0.06 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 15 | |||||
Operating Margin % | 2.46 | |||||
Net Margin % | 4.9 | |||||
FCF Margin % | -9.64 | |||||
ROE % | 3.65 | |||||
ROA % | 1.79 | |||||
ROIC % | 1.41 | |||||
ROC (Joel Greenblatt) % | 7.35 | |||||
ROCE % | 3.35 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 127.37 | |||||
PE Ratio without NRI | 172.86 | |||||
Price-to-Owner-Earnings | 302.5 | |||||
PS Ratio | 4.97 | |||||
PB Ratio | 4.75 | |||||
Price-to-Tangible-Book | 5.15 | |||||
EV-to-EBIT | 103.97 | |||||
EV-to-EBITDA | 103.97 | |||||
EV-to-Revenue | 6.33 | |||||
EV-to-FCF | -63.97 | |||||
Price-to-Projected-FCF | 2.72 | |||||
Price-to-Median-PS-Value | 1.2 | |||||
Price-to-Graham-Number | 6.37 | |||||
Earnings Yield (Greenblatt) % | 0.96 | |||||
FCF Yield % | -1.5 | |||||
Forward Rate of Return (Yacktman) % | -43.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Kangmei Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 5,213.453 | ||
EPS (TTM) (Â¥) | 0.019 | ||
Beta | 0.77 | ||
Volatility % | 33.29 | ||
14-Day RSI | 58.54 | ||
14-Day ATR (Â¥) | 0.126548 | ||
20-Day SMA (Â¥) | 2.3825 | ||
12-1 Month Momentum % | 2.6 | ||
52-Week Range (Â¥) | 1.68 - 2.93 | ||
Shares Outstanding (Mil) | 13,863.87 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kangmei Pharmaceutical Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Kangmei Pharmaceutical Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Kangmei Pharmaceutical Co Ltd Frequently Asked Questions
What is Kangmei Pharmaceutical Co Ltd(SHSE:600518)'s stock price today?
When is next earnings date of Kangmei Pharmaceutical Co Ltd(SHSE:600518)?
Does Kangmei Pharmaceutical Co Ltd(SHSE:600518) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |